维普中文期刊产品整合服务
20篇 您的检索式:作者名="Shibui M"
    题名 作者 年代 出处 被引量
1Application of antisense ribonucleic acid complementary to O6-methylguanine-deoxyribonucleic acid methyltransferase messenger ribonucleic acid for therapy of malignant gliomas显示文摘NAGANE M ASAI A SHIBUI S 1997Neurosurgery1997,41,2:1
2Applicaton of antisense ribonucleic acid complementary to 06-methylguanine-deoxyribonucleic acid rnethyltransferase messenger ribonucleic acid for therapy of malignant glionas 显示文摘Nangane M Asai A Shibui S 1997Neurosurgery1997,41,2:1
3Effects of interface edge configuration on residual stress in the bonded structures for a divertor application显示文摘Kitamura K Nagata K Shibui M 1998Journal of nuclear materials1998,,1998:1
4Effects of interface edge configuration on residual stress in the bonded structures for a divertor application 显示文摘Kitamura K Nagata K Shibui M 1998Journal of Nuclear Materials1998,258,263:1
5In vitro selection of a peptide inhibitor of human IL-6 using mRNA display显示文摘Kobayashi T Kakui M Shibui T 2011Mo- lecular bioteehnology2011,48,2:1
6Ossified and calcified epidural hematoma incidentally found 40 years after head injury : case report显示文摘Nagane M Oyama h shibui S 1994Surg Neurol1994,42,:1
7Malignant intracerebral nerve sheath tumor with intratumoral calcification:case report显示文摘Tanaka M Shibui S Nomura K 2000J Neurosurg2000,92,:1
8Effect of long-term nitrate treatment on cardiac events in patients with vasospastic angina 显示文摘Kosugi M Nakagomi A Shibui T 2011Circ J2011,75,9:1
9Solitary plasmacytoma of the skull:a case report显示文摘TANAKA M SHIBUI S NOMURA K 1998Japanese J Clinical Oncology1998,28,10:1
10Expression pattern of chemoresistance-related for proper selection of anticancer drugs显示文摘Nagane M Asai A Shibui S 1999Jpa J Clin Oncol1999,29,1:1
11Skull base malignant lymphoma: a case report and review of theliterature显示文摘OYAMA H NAGANE M SHIBUI S 1992Jpn J Clin Oncol1992,22,:1
12Expression pattern of chemoresistance-related genes in human malignant brain tumors:a working knowledge for proper selection of anticancer drugs显示文摘Nagane M Asai A Shibui S 1999Jpn J Clin Oncol1999,29,11:1
13Diurnal fluctuation of sleep propensity and hormonal secretion across the menstrual cycle显示文摘Shibui K Uchiyama M Okawa M 2000Biol Psychiatry2000,48,11:1
14Application of antisense ribonucleic acid complementary to 06 - Methylguanine - deoxyibonucleic acid methyltransferase messenger ribonucleic acid for therapy of malignant gJiomas显示文摘Nagane M Asai A Shibui S 1997Neurosurgery1997,41,2:1
15Overweight and obesity accelerate the progression of IgA nephropathy: prognostic utility of a combination of BMI and histopathological parameters显示文摘Kataoka H Ohara M Shibui K 2012Clin Exp Nephrol2012,16,5:1
16Effects of interface edge configuration on residual stress in the bonded structures for a divertor application显示文摘Kitamura K Nagata K Shibui M 1998Journal of Nuclear Materials1998,263,:1
17Expression pattern of chemoresistance related for proper selection of anticancer drugs显示文摘Nagane M Asai A Shibui S 1999Jpa J Clin Oncol1999,29,1:1
18Apllication of antisense ribonucleic acid complementary to O6-methylguanine -deoxyribonucleic acid methyltransferase messenger ribonucleic acid for therapy of maliglant glionas显示文摘Yoshinaga M Asai A Shibui S 1997Neurosurgery1997,41,2:1
19Effects of interface edge configuration on residual stress in the bonded structures for a divertor application显示文摘KITAMURA K NAGATA K SHIBUI M 1998Journal of Nuclear Materials1998,263,238:1
20Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305)显示文摘Objectives: Glioblastoma(GBM) is one of the worst cancers in terms of prognosis.Standard therapy consists of resection with concomitant chemoradiotherapy.Resistance to nimustine hydrochloride(ACNU),an alkylating agent,has been linked to methylguanine DNA methyltransferase(MGMT).Daily administration of procarbazine(PCZ) has been reported to decrease MGMT activity.This study investigated the efficacy of ACNU + PCZ compared to ACNU alone for GBM and anaplastic astrocytoma(AA).Methods: Patients(20-69 years) who had newly diagnosed AA and GBM were randomly assigned to receive radiotherapy with ACNU alone or with ACNU + PCZ.The primary endpoint was overall survival(OS).This was designed as a phase Ⅱ/Ⅲ trial with a total sample size of 310 patients and was registered as UMIN-CTR C000000108.Results: After 111 patients from 19 centers in Japan were enrolled,this study was terminated early because temozolomide was newly approved in Japan.The median OS and median progression-free survival(PFS) with ACNU alone(n = 55) or ACNU + PCZ(n = 56) in the intention-to-treat population were 27.4 and 22.4 months(P = 0.75),and 8.6 and 6.9 months,respectively.The median OS and median PFS of the GBM subgroup treated with ACNU alone(n = 40) or ACNU + PCZ(n = 41) were 19.0 and 19.5 months,and 6.2 and 6.3 months,respectively.Grade 3/4 hematologic adverse events occurred in more than 40% of patients in both arms,and 27% of patients discontinued treatment because of adverse events.Conclusions: The addition of PCZ to ACNU was not beneficial,in comparison with ACNU alone,for patients with newly diagnosed AA and GBM.Shibui S Narita Y Mizusawa J Beppu T Ogasawara K Sawamura Y Kobayashi H Nishikawa R Mishima K Muragaki Y Maruyama T Kuratsu J Nakamura H Kochi M Minamida Y Yamaki T Kumabe T Tominaga T Kayama T Sakurada K Nagane M Kobayashi K Nakamura H Ito T Yazaki T Sasaki H Tanaka K Takahashi H Asai A Todo T Wakabayashi T Takahashi J Takano S Fujimaki T Sumi M Miyakita Y Nakazato Y Sato A Fukuda H Nomura K 2013中国神经肿瘤杂志2013,11,1:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费